Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

Recurrent chromosomal rearrangements have not been well characterized in common
carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal …

Abstract Characterization of the prostate cancer transcriptome and genome has identified
chromosomal rearrangements and copy number gains and losses, including ETS gene family …

The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling
cellular memory and has been linked to aggressive prostate cancer. Here we investigate the …

An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy
in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low to …

Breast cancer is the most prevalent cancer in women, and over two-thirds of cases express
estrogen receptor-α (ER-α, encoded by ESR1). Through a prospective clinical sequencing …

Despite efforts to profile prostate cancer, the genetic alterations and biological processes
that correlate with the observed histological progression are unclear. Using laser-capture …

Recently, we identified recurrent gene fusions involving the 5′ untranslated region of the
androgen-regulated gene TMPRSS2 and the ETS (E26 transformation-specific) family genes …

Chromosomal rearrangements fusing the androgen-regulated gene TMPRSS2 to the oncogenic
ETS transcription factor ERG occur in approximately 50% of prostate cancers, but how …

TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer.
Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo …